The Financial Reality of Dog Cloning
Commercial dog cloning is primarily offered by ViaGen Pets and Sooam Biotech Research Foundation. ViaGen Pets lists its dog cloning service at approximately $50,000, plus a $1,500 cell preservation fee. Sooam Biotech, based in South Korea, has cloned over 1,000 dogs since 2005 and charges a similar premium. These prices do not include ongoing veterinary care for the cloned puppy, which often requires immediate medical attention due to developmental issues. The high cost is driven by the complex somatic cell nuclear transfer process, which has a low success rate and requires multiple surrogate mothers. For most pet owners, the financial burden of cloning is a primary source of regret, especially when the cloned dog does not replicate the original pet's temperament or personality.
The cloning industry remains a niche luxury market, with ViaGen Pets and Sooam Biotech as the dominant commercial providers. The American Kennel Club does not recognize cloned dogs in conformation shows, and cloned dogs cannot be registered as purebreds through traditional means. This lack of official recognition limits the perceived value of a cloned pet for breeders and show enthusiasts. Additionally, the cost of cloning a dog is significantly higher than the cost of adopting a similar breed from a shelter, which typically ranges from $50 to $500. The financial disparity between cloning and adoption is a key factor in why many owners express regret after the cloning process is complete.
Health Risks and Welfare Concerns
Cloned dogs frequently suffer from health complications linked to the cloning process. A landmark study published in the journal Nature in 2008 documented that cloned animals often experience early-onset obesity, immune deficiencies, and organ failure. Sooam Biotech's own data indicates that cloned puppies have a higher mortality rate in the first weeks of life compared to naturally conceived dogs. The surrogate mothers also face significant risks, including complications from embryo implantation and cesarean deliveries. These welfare concerns are a major reason why veterinary organizations and animal rights groups oppose commercial pet cloning.
The FDA regulates animal cloning in the United States as a veterinary biologics product, but it does not require specific labeling for food products from cloned animals or their offspring. The Center for Veterinary Medicine at the FDA states that cloned animals and their offspring are no different from other animals in terms of food safety. However, the ethical debate continues, with the American Veterinary Medical Association noting that the cloning process involves the creation and destruction of many embryos to produce a single viable clone. This high loss rate is a central point of contention for animal welfare advocates and contributes to the ethical regret expressed by some pet owners.
Why Owners Regret the Decision
The primary reason owners regret cloning their dog is the misunderstanding of what cloning actually produces. A cloned dog is a genetic twin of the original pet, born at a different time, not a resurrected version of the same individual. The clone will have a different personality, shaped by its own unique experiences and environment. This genetic determinism myth is a common pitfall, as pet owners often expect the clone to replicate the exact behaviors and bond of the original dog. The emotional disappointment when the clone develops a different temperament is a frequent theme in owner testimonials and consumer reviews of cloning services.
Consumer protection advocates have raised concerns about the marketing practices of commercial cloning companies. The Federal Trade Commission has not issued specific rulings on pet cloning advertising, but general guidelines against deceptive practices apply. Companies like ViaGen Pets market cloning as a way to "save" a beloved pet, which critics argue preys on the grief of pet owners. The lack of long-term studies on the psychological well-being of cloned dogs also leaves a gap in the data. For consumers considering this option, reviewing the terms of service and understanding the scientific limitations is critical before committing to the procedure, as highlighted by consumer education resources on the FTC website